Abstract
Epinine (N-methyl-dopamine, the active metabolite of ibopamine), is a full agonist at dopamine (DA)-receptors and α- and \-adrenoceptors. To study whether in vivo DA-receptor mediated effects can be separated from α- and \-adrenoceptor effects we compared in 10 male volunteers the effects of i.v. epinine (0.5; 1; 2; 4 μg/kg/min for 15 min each) on DA-receptor (changes in serum prolactin)- and α- and \-adrenoceptor (changes in systolic [Psyst] and diastolic blood pressure [Pdiast] and heart rate)-mediated effects with those of dopamine before and after propranolol (5 mg i.v. 45 min pre-infusion), bisoprolol (15 mg p.o. 2 h preinfusion) and domperidone (10 mg p.o. 1 h pre-infusion). At the 0.5 and 1 μg doses dopamine and epinine did not affect Psyst Pdiast and heart rate but significantly decreased prolactin levels. At the higher dose both dopamine and epinine significantly increased Psyst and heart rate, while only epinine significantly increased Pdiast. In addition both dopamine and epinine significantly increased diuresis and natriuresis; in contrast, only dopamine, but not epinine, dose-dependently increased plasma noradrenaline levels. Domperidone did not affect dopamine- and epinine-evoked blood pressure-and heart rate-changes, but antagonized their prolactin-effects (at least at the lower doses). Bisoprolol and propranolol significantly reduced dopamine-induced Psyst- and heart rate-increases to about the same extent. Propranolol enhanced epinine-induced Psyst-and Pdiast-increases while bisoprolol reduced epinine-evoked Psyst-increase but not Pdiast-increase. Epinine-induced heart rate-increase was abolished by bisoprolol and was converted into a heart rate-decrease by propranolol. We conclude that in 0.5 and 1 μg doses (plasma levels of 20–80 nmol/1) epinine acts only at DA-receptors. Thus, ibopamine in therapeutically recommended doses (3 × 100 mg/day with peak plasma epinine-levels of 50–80 nmol/1) very likely activates only DA-receptors. In higher doses, however, epinine -like dopamine - activates α- and \-adrenoceptors whereby epinine has a stronger α-adrenoceptor agonistic activity than dopamine. Moreover, part of the dopamine-effects are indirect via release of endogenous noradrenaline whereas epinine-effects do not appear to include an indirect component.
Similar content being viewed by others
References
Anderson FL, Port JD, Reid BB, Hanson G, Kralios AC, Hershberger RE, Bristow MR (1992) Effect of therapeutic dopamine administration on myocardial catecholamine and neuropeptide Y concentrations in the failing ventricles of patients with idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol 20:800–806
Ben-Jonathan N (1985) dopamine; a prolactin-inhibiting hormone, Endocrinol Rev 6:564–589
Benker G, Jaspers C, Häusler G, Reinwein D (1990) Control of prolactin secretion - Rev Klin Wochenschr 68:1157–1167
Boomsma F, Alberts G, van der Hoorn FAJ, Man in't Veld AJ, Schalekamp MADH (1992) Simultaneous determination of free catecholamines and epinine and estimation of total epinine and dopamine in plasma and urine by high-performance liquid chromatography with fluorometric detection. J Chromatogr 574:109–117
Bravo G, Ghyel-Burton J, Jaumin P, Godfraind T (1991) A comparison of the inotropic effects of dopamine and epinine in human isolated cardiac preparations. J Pharmacol Exp Ther 257: 439–443
Brodde O-E, Inui J, Motomura S, Schümann HJ (1980) The mode of direct action of dopamine in the rabbit heart. J Cardiovasc Pharmacol 2:567–582
Brodde O-E, Motomura S, Schümann HJ (1979) Studies on the mechanism of the positive inotropic action evoked by epinine on the rabbit isolated papillary muscle at different rates of beating. Clin Exp Pharmacol Physiol 6:41–51
Brodde O-E, Klusmann I, Wojcik M, Man in't Veld AJ, Boomsma F, Michel MC (1993) Lack of desensitization of α- and \-adrenoceptor function during chronic treatment of healthy volunteers with ibopamine, an orally active dopamine receptor agonist. Eur J Clin Pharmacol 44:283–286
Brodde O-E (1990) Affinities of dopamine agonists and antagonists for peripheral dopamine receptors. In: JP Hieble (ed) Cardiovascular function of peripheral dopamine receptors. Marcel Dekker, New York Basel, pp 27–74
Brodde O-E (1986) Bisoprolol (EMD 33512), a highly selective \1-adrenoceptor antagonist: in vitro and in vivo studies. J Cardiovasc Pharmacol 11 [Suppl 11]:S29-S35
Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS (1982) Domperidone. Drugs 24:360–400
Brown L, Lorenz B, Erdmann E (1985) The inotropic effects of dopamine and its precursor levodopa on isolated human ventricular myocardium. Klin Wochenschr 63:1117–1123
Carey RM (1990) Dopaminergic control of aldosterone secretion. In: Hieble JP (ed) Cardiovascular function of peripheral dopamine receptors. Marcel Dekker, New York Basel, pp 297–314
Casagrande C, Merlo L, Ferrini R, Miragoli G, Semeraro C (1989) Cardiovascular and renal action of dopaminergic prodrugs. J Cardiovasc Pharmacol 14 [Suppl 8]:S40-S59
Daul A, Hermes U, Schäfers RF, Wenzel R, Von Birgelen C, Brodde O-E (1995) The \-adrenoceptor subtype(s) mediating adrenaline-and dobutamine-induced blood pressure and heart rate changes in healthy volunteers. Int J Clin Pharmacol Ther 33:140–148
Deighton NM, Motomura S, Bals S, Zerkowski H-R, Brodde O-E (1992) Characterization of the beta adrenoceptor subtype(s) mediating the positive inotropic effects of epinine, dopamine, dobutamine, denopamine and xamoterol in isolated human right atrium. J Pharmacol Exp Ther 262:532–538
English TAH, Gristwood RW, Owen RAA, Sampford KA, Wallwork J (1986) Effects of dopamine on human ventricle in vitro: Comparison with effects of isoprenaline, epinine and ibopamine (Abstract). Br J Pharmacol 87: [Suppl] 203 P
Ensinger H, Lindner KH, Goertz A, Grünert A, Ahnefeld FW, Georgieff M (1993) Metabolic and haemodynamic effects of dopamine plus domperidone in volunteers. Res Exp Med 193:241–254
Girbes ARJ, Van Veldhuisen DJ, Grevink RG, Smit AJ, Reitsma WD (1992) Effects of ibopamine on exercise induced increase in norepinephrine in normal men. J Cardiovasc Pharmacol 19:371–374
Goldberg LI, Kohli JD (1983) Peripheral dopamine receptors: a classification based on potency series and specific antagonism. Trends Pharmacol Sci 4:64–66
Goldberg LI (1972) Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev 25:1–29
Goldberg LI (1989) The role of dopamine receptors in the treatment of congestive heart failure. J Cardiovasc Pharmacol 14 [Suppl 5]:S19-S27
Hasenfuss G, Kasper W, Meinertz T, Busch W, Lehmann M, Kruse T, Hofmann T, Revenaugh M, Holubarsch C, Just H (1987) Evaluation of long-term oral levodopa therapy in chronic congestive heart failure. Klin Wochenschr 65:1087–1094
Henwood JM, Todd PA (1989) Ibopamine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 36:11–31
Hilditch A, Drew GM (1985) Peripheral dopamine receptor subtypes — a closed look. Trends Pharmacol Sci 6:396–400
Huang Y-C, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants JP (1986) Pharmacokinetics and dose proportionality of domperidone in healthy volunteers. J Clin Pharmacol 26:628–632
Katz AM (1986) Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation 73 [Suppl III]: III-184-III-190
Kayanakis JG and the European Ibopamine Study Group (1991) Six-month treatment of congestive heart failure with ibopamine. A double-blind randomized, placebo-controlled, multicenter trial. Am J Noninvasice Cardiol 5:35–41
Kohli JD, Glock D, Goldberg LI (1983) Selective DA2 versus DA1 antagonist activity of domperidone in the periphery. Eur J Pharmacol 89:137–141
Lee MR (1993) Dopamine and the kidney: ten years on. Clin Sci 84:357–375
Levinson PD, Goldstein DS, Munson PJ, Gill JR, Keiser HR (1985) Endocrine, renal and hemodynamic responses to graded dopamine infusions in normal men. J Clin Endocrinol Metab 60:821–826
Lokhandwala MF, Amenta F (1991) Anatomical distribution and function of dopamine receptors in the kidney. FASEB J 5:3023–3030
Lokhandwala MF, Barrett RJ (1982) Cardiovascular dopamine receptors: physiological, pharmacological and therapeutic implications. J Anton Pharmacol 3:189–215
Lorenzi M, Karam JH, Tsalikian E, Bohannon NV, Gerich JE, Forsham PH (1979) Dopamine during α- or β-adrenergic blockade in man. J Clin Invest 63:310–317
Mugelli A, Ledda F, Mantelli L, Torrini M, Maccioni T (1977) Studies on the positive inotropic effect of dopamine in the guinea-pig heart. Naunyn Schmiedeberg's Arch Pharmacol 301:49–55
Nichols AJ, Ruffolo RR (1987) Evulation of the alpha and beta adrenoceptor-mediated activities of the novel, orally active inotropic agent, ibopamine, in the cardiovascular system of the pithed rat: comparison with epinine and dopamine. J Pharmacol Exp Ther 242:455–463
Os I, Kjeldsen SE, Westheim A, Lande K, Norman N, Hjermann I, Eide I (1987) Endocrine and haemodynamic responses to graded dopamine infusion in essential hypertension. Scand J Clin Lab Invest 47:371–377
Packer M (1992) Pathophysiology of chronic heart failure. Lancet 340:88–92
Pernet A, Hammond VA, Blesa-Malpica G, Burrin J, Orskov H, Alberti KGMM, Johnston DG (1984) The metabolic effects of dopamine in man. Eur J Clin Pharmacol 26:23–28
Port JD, Gilbert EM, Larrabee P, Mealey P, Volkmann K, Ginsburg R, Hershberger RE, Murray J, Bristow MR (1990) Neurotransmitter depletion compromises the ability of indirect-acting amines to proviede inotropic support in the failing human heart. Circulation 81:929–938
Rajfer SI, Fetima RD (1990) Role of dopamine receptors and the utility of dopamine agonists in heart failure. Circulation 82:97–102
Rajfer SI, Rossen JD, Douglas FL, Goldberg LL Karrison T (1986) Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyl-dopamine and to plasma catecholamine levels. Circulation 73:740–748
Rajfer SI, Rossen JD, Nemanich JW, Douglas FL, Davis F, Osinski J (1987) Sustaind hemodynamic improvement during long-term therapy with levodopa in heart failure: role of plasma catecholamines. J Am Coll Cardiol 10:1286–1293
Rousseau MF, Raigoso J, van Eyll Ch, Van Mechelen H, Musso NR, Lotti G, Pouleur H (1992) Effects of intravenous epinine administration on left ventricular systolic performance, coronary hemodynamics, and circulating catecholamines in patients with heart failure. J Cardiovasc Pharmacol 19:155–162
Schwinger RHG, Böhm M, Schulz Ch, Schmidt U, Schmid B, Dienemann H, Reichart B, Erdmann E (1993) Cardiac inotropic as well as coronary and pulmonary artery actions of epinine in human isolated tissues. J Pharmacol Exper Ther 265:346–357
Smit AJ, Meijer S, Wesseling H, Donker AJM, Reitsma WD (1988) Effect of metoclopramide on dopamine-induced changes in renal function in healthy controls and in patients with renal disease. Clin Sci 75:421–428
Spencer C, Faulds D, Fitton A (1993) Ibopamine. Drugs & Aging 3:556–584
Taylor SH (1989) Pharmacotherapeutic profile of ibopamine in heart failure. J Cardiovasc Pharmacol 14 [Suppl. 8]:5118–5123
Van Veldhuisen DJ, Girbes ARJ, Crijns HJ, Smit AJ, Van Gilst WH, Lie KI (1991) The oral dopamine agonist, ibopamine, in normal man: effects on rhythm, heart rate, blood pressure and catecholamines. Int J Clin Pharmacol Res 11:159–165
Willems JL, Buylaert WA, Lefebvre RA, Bogaert MG (1985) Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in the gastrointestinal system. Pharmacol Rev 37:165–216
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Daul, A., Elter-Schulz, M., Poller, U. et al. Dose-dependent separation of dopaminergic and adrenergic effects of epinine in healthy volunteers. Naunyn-Schmiedeberg's Arch Pharmacol 352, 429–437 (1995). https://doi.org/10.1007/BF00172781
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00172781